Contrasting Monte Rosa Therapeutics (NASDAQ:GLUE) and Krystal Biotech (NASDAQ:KRYS)

Monte Rosa Therapeutics (NASDAQ:GLUE) and Krystal Biotech (NASDAQ:KRYS) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, institutional ownership, earnings, profitability and dividends.

Insider & Institutional Ownership

80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 6.4% of Monte Rosa Therapeutics shares are owned by company insiders. Comparatively, 13.1% of Krystal Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Monte Rosa Therapeutics and Krystal Biotech”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monte Rosa Therapeutics	$28.73 million	30.05	-$38.63 million	($1.76)	-5.75
Krystal Biotech	$389.13 million	25.10	$204.83 million	$7.98	41.35

Krystal Biotech has higher revenue and earnings than Monte Rosa Therapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Monte Rosa Therapeutics and Krystal Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Monte Rosa Therapeutics	-560.85%	-43.31%	-27.59%
Krystal Biotech	54.82%	19.34%	17.65%

Analyst Recommendations

This is a summary of current recommendations and price targets for Monte Rosa Therapeutics and Krystal Biotech, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monte Rosa Therapeutics	1	2	8	1	2.75
Krystal Biotech	0	2	10	2	3.00

Monte Rosa Therapeutics presently has a consensus target price of $26.67, indicating a potential upside of 163.50%. Krystal Biotech has a consensus target price of $377.20, indicating a potential upside of 14.30%. Given Monte Rosa Therapeutics’ higher probable upside, analysts plainly believe Monte Rosa Therapeutics is more favorable than Krystal Biotech.

Risk & Volatility

Monte Rosa Therapeutics has a beta of 1.37, indicating that its share price is 37% more volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500.

Summary

Krystal Biotech beats Monte Rosa Therapeutics on 12 of the 15 factors compared between the two stocks.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

About Krystal Biotech

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.